Details for New Drug Application (NDA): 018115
✉ Email this page to a colleague
NDA 018115 describes TRIAMINIC-12, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the TRIAMINIC-12 profile page.
The generic ingredient in TRIAMINIC-12 is chlorpheniramine maleate; phenylpropanolamine hydrochloride. There are twenty-nine drug master file entries for this compound. Additional details are available on the chlorpheniramine maleate; phenylpropanolamine hydrochloride profile page.
The generic ingredient in TRIAMINIC-12 is chlorpheniramine maleate; phenylpropanolamine hydrochloride. There are twenty-nine drug master file entries for this compound. Additional details are available on the chlorpheniramine maleate; phenylpropanolamine hydrochloride profile page.
Summary for 018115
| Tradename: | TRIAMINIC-12 |
| Applicant: | Novartis |
| Ingredient: | chlorpheniramine maleate; phenylpropanolamine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 12MG;75MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
